Value of severity scales in predicting mortality from community-acquired pneumonia: Systematic review and meta-analysis

Thorax

Volumn 65, Issue 10, 2010, Pages 884-890

  Loke, Yoon K ^a,b   Kwok, Chun Shing ^a   Niruban, Alagaratnam ^b   Myint, Phyo K ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

BREATHING RATE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HUMAN; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 77957197403     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.134072     Document Type: Review

References (37)

1. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997;10:1530-4.
2. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000;55:219-23.
3. Kamath A, Pasteur MC, Slade MG, et al. Recognising severe pneumonia with simple clinical and biochemical measurements. Clin Med 2003;3:54-6.
4. Myint PK, Kamath AV, Vowler SL, et al. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts. Age Ageing 2006;35:286-91.
5. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
6. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
7. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388,406 patients. Thorax 2009;64:1062-9.
8. Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004;59:421-7.
9. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
10. Chappell FM, Raab GM, Wardlaw JM. When are summary ROC curves appropriate for diagnostic meta-analyses? Stat Med 2009;28:2653-68.
11. Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80.
12. Sousa ML, Ribeiro AR. Systematic review and meta-analysis of diagnostic and prognostic studies: a tutorial. Arq Bras Cardiol 2009;92:229-38.
13. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
14. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118:384-92. (Pubitemid 40460997)
15. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007;62:253-9. (Pubitemid 46579808)
16. Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260:93-101. (Pubitemid 43894075)
17. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006;27:151-7. (Pubitemid 43092679)
18. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008;46:1513-21.
19. Etzion O, Novack V, Avnon L, et al. Characteristics of low-risk patients hospitazed with community-acquired pneumonia. Eur J Intern Med 2007;18:209-14.
20. Gutierrez F, Masia M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005;11:778-800.
21. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52:48-58.e2.
22. Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008;87:329-34.
23. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349-55.
24. Man SY, Lee N, Ip N, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007;64:348-53.
25. Menendez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91.
26. Myint PK, Sankaran P, Musonda P, et al. Performance of CURB-65 and CURB-age in community-acquired pneumonia. Int J Clin Pract 2009;63:1345-50.
27. Pilotto A, Addante F, Ferrucci L, et al. The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia. J Geriatrol A Biol Sci Med Sci 2009;64A:880-7.
28. Renaud B, Coma E, Labarere J, et al. Routine use of the Pneumonia Severity Index for the guiding the site-of-treatment decision of patients with pneumonia in the emergency departments: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007;44:41-9.
29. Renaud B, Coma E, Hayon J, et al. Investigation of the ability of the Pneumonia Severity Index to accurately predict clinical relevant outcomes: a European study. Clin Microbiol Infect 2007;13:923-31.
30. Reyes Calzada S, Martinez Tomas R, Cremades Romero MJ, et al. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med 2007;101:1909-15.
31. Schuetz P, Koller M, Chirst-Crain M, et al. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect 2008;136:1628-37.
32. van der Eerden MM, de Graaff CS, Bronsveld W, et al. Prospective evaluation of pneumonia severity index in hospitalized patients with community-acquired pneumonia. Respir Med 2004;98:872-8.
33. Zuberi FF, Khan JA. Prospective comparison of prediction rules of risk for CAP in a developing country. Int J Tuberc Lung Dis 2008;12:447-52.
34. Niederman MS. Making sense of scoring systems in community acquired pneumonia. Respirology 2009;14:327-35.
35. Agency for Healthcare Research and Quality. Pneumonia severity index calculator. Rockville, Maryland, 2003. http://pda.ahrq.gov/psicalc.asp (accessed 16 Nov 2009).
36. Altman DG, Bland M. Diagnostic tests 2: Predictive values. BMJ 1994;309:102.
37. Dinnes J, Deeks J, Kirby J, et al. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 2005;9:1-113.